ECTRIMS Symposium Highlights
Advancing MS care: New treatments and technologies

What can we do to further customise care for people with MS now and in the future? In this virtual satellite symposium moderated by Thomas Berger, Joep Killestein and Jiwon Oh navigate:

  • The latest possibilities for tailored approaches to treatment

  • What the future may bring for personalised MS care by updating us on digital innovations for disease monitoring

  • Insights and examples of how advances in artificial intelligence could enhance clinical care

What treatments and strategies are becoming available
to improve the individual patient experience with customised MS care?

What established therapies have been modified to give clinicians the possibility to better customise their care for people with MS? How can extended interval dosing with a monoclonal antibody targeting VLA-4 support a more personalised approach to treatment? Professor Joep Killestein discusses initial results from clinical trials investigating the relevant outcomes observed with next generation MS therapies. He also dives into new considerations in MS treatment decision making, starting with the latest insights around every 6-week dosing with anti-VLA4 therapy, followed by discussing the relevance of MS patient immune function in the COVID era.

Thomas Berger

Thomas Berger MD, MSc (Chair)

Medical University of Vienna
Vienna, Austria

Joep Kilestein

Joep Killestein MD, PhD

Amsterdam University Medical Center
Amsterdam, Netherlands

How can we better personalise MS care now and in the future?

Are you up to date on how next-generation MS therapies may improve patient outcomes?

You might wonder - is there a difference in the efficacy and safety profiles of anti-VLA4 therapy when different routes of administration are used?

SC administration of an established IV therapy – what's in it for me and my patients?

Are you aware of how extending the dosing interval of anti-VLA4 therapy is impacting the risk of PML in MS patients?

Must know: Insights on extended dosing intervals from the NOVA study part I

What is one of the latest considerations in MS care?

Watch the full video

What digital tools are currently in development to better monitor and support patients in MS care?

How can digital tools help clinicians better understand how each of their patients are doing between visits and hence assess whether their disease is adequately controlled? Are there some examples of promising digital applications? Professor Killestein describes initial results with three applications: Konectom (a research tool), Neurokeys and MS Sherpa (both apps available in certain countries), that are currently being assessed for their applicability in measuring important outcomes in people with MS and providing validated, interpretable data.

Thomas Berger

Thomas Berger MD, MSc (Chair)

Medical University of Vienna
Vienna, Austria

Joep Kilestein

Joep Killestein MD, PhD

Amsterdam University Medical Center
Amsterdam, Netherlands

Do you know the advantages of digital monitoring for people with MS?

Are you aware of the digital applications being assessed to measure outcomes in MS?

Are we there yet in clinical practice and which apps should we choose to use or recommend?

Watch the full video

Can artificial intelligence (AI) enhance clinical care for people with multiple sclerosis (MS)?

Can artificial intelligence (AI) shape the future of personalised MS care? Where does the latest technology of deep learning have the greatest clinical utility? Associate Professor Jiwon Oh discusses how AI can be used to help healthcare professionals in their everyday practice and explores ways that deep learning could predict disease activity, treatment outcomes and help to personalise disease prognosis.

Thomas Berger

Thomas Berger MD, MSc (Chair)

Medical University of Vienna
Vienna, Austria

Jiwon Oh

Jiwon Oh MD, PhD

Keenan Research Centre of the
Li Ka Shing Knowledge Institute
Toronto, Canada

Have you considered how AI can benefit your clinical approach to managing MS?

What are some applications of AI and deep learning in everyday clinical practice?

Did you know that deep learning can be used to extract specific information from dictated clinic notes?

Are you aware that deep learning using Phase 3 trial imaging data has resulted in a new classification of MS subtypes predicting patient prognosis and treatment response?

Did you know that AI can now predict active and slowly expanding lesions using information not visible to the human eye in standard MRI images?

Are you looking forward to AI improving data management and ultimately your time management?

What do you see as the main factors taking us into a new era of personalising MS care?

Watch the full video

Biogen-130852.
Date of preparation: October 2021.